ENTA FY1Q18 results: http://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-12 Revenue was $38.1M, of which $23.1M came from royalties and $15.0M from a milestone payment for Mavyret approval in Japan. GAAP EPS was $0.59. Cash at 12/31/17 was $297.5M. Gross operating expenses were $23.7M—well below the FY2018 quarterly guidance range of $30.5-34.5M.